Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.

Breast cancer research : BCR - 15 Aug 2021

Brett Jamie O, Spring Laura M, Bardia Aditya, Wander Seth A

Abstract excerpt

In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase inhibition. How these mutations affect tumor sensitivity to established and novel therapies are active areas of research. These therapies include estrogen receptor-targeting agents, such as selective estrogen receptor modulators, covalent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Aromatase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinases

Share to Estrogen Receptor alpha

Share to Mechanistic Target of Rapamycin Complex 1

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Receptors, Estrogen

Share to Selective Estrogen Receptor Modulators

Source

Open in PubMed Open full text

Identifiers

PMID: 34392831
DOI: 10.1186/s13058-021-01462-3
PMCID: PMC8365900

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.PMID 34392831Read ↗

ESR1 mutations in breast cancerSemantic proximity Read ↗

ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.Semantic proximity Read ↗

The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.Semantic proximity Read ↗

The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.Semantic proximity Read ↗

Implications of ESR1 Mutations in Hormone Receptor-Positive Breast Cancer.Semantic proximity Read ↗

ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.Semantic proximity Read ↗

Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists.Semantic proximity Read ↗

ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients.Semantic proximity Read ↗

Estrogen receptor mutations and their role in breast cancer progression.Semantic proximity Read ↗

Evaluating the investigational drug landscape for ESR1-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.Semantic proximity Read ↗

ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis.Semantic proximity Read ↗

Activating ESR1 mutations in hormone-resistant metastatic breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.